AP2607A - Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists - Google Patents

Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists

Info

Publication number
AP2607A
AP2607A AP2008004441A AP2008004441A AP2607A AP 2607 A AP2607 A AP 2607A AP 2008004441 A AP2008004441 A AP 2008004441A AP 2008004441 A AP2008004441 A AP 2008004441A AP 2607 A AP2607 A AP 2607A
Authority
AP
ARIPO
Prior art keywords
pyridazin
piperidin
receptor antagonists
ylamine derivatives
fast dissociating
Prior art date
Application number
AP2008004441A
Other languages
English (en)
Other versions
AP2008004441A0 (en
Inventor
Marcel Frans Leopold De Bruyn
Gregory James Macdonald
Ludo Edmond Josephine Kennis
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AP2008004441A0 publication Critical patent/AP2008004441A0/xx
Application granted granted Critical
Publication of AP2607A publication Critical patent/AP2607A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AP2008004441A 2005-10-26 2006-10-24 Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists AP2607A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05110028 2005-10-26
EP06100209 2006-01-10
EP06101545 2006-02-10
PCT/EP2006/067696 WO2007048779A1 (en) 2005-10-26 2006-10-24 Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists

Publications (2)

Publication Number Publication Date
AP2008004441A0 AP2008004441A0 (en) 2008-04-30
AP2607A true AP2607A (en) 2013-03-05

Family

ID=35734993

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004441A AP2607A (en) 2005-10-26 2006-10-24 Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists

Country Status (34)

Country Link
US (3) US8940743B2 (es)
EP (1) EP1943242B1 (es)
JP (1) JP5140598B2 (es)
KR (1) KR101351910B1 (es)
CN (1) CN101291925B (es)
AP (1) AP2607A (es)
AR (1) AR058151A1 (es)
AT (1) ATE495167T1 (es)
AU (1) AU2006307930B2 (es)
BR (1) BRPI0617787A2 (es)
CA (1) CA2623160C (es)
CR (1) CR10020A (es)
CY (1) CY1111977T1 (es)
DE (1) DE602006019624D1 (es)
DK (1) DK1943242T3 (es)
EA (1) EA015681B1 (es)
EC (1) ECSP088396A (es)
ES (1) ES2359020T3 (es)
GT (1) GT200800033A (es)
HN (1) HN2008000646A (es)
HR (1) HRP20110226T1 (es)
IL (1) IL191016A (es)
JO (1) JO2769B1 (es)
MY (1) MY145609A (es)
NO (1) NO20082350L (es)
NZ (1) NZ566785A (es)
PL (1) PL1943242T3 (es)
PT (1) PT1943242E (es)
RS (1) RS51674B (es)
SI (1) SI1943242T1 (es)
TW (1) TWI399373B (es)
UA (1) UA94058C2 (es)
WO (1) WO2007048779A1 (es)
ZA (1) ZA200803668B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
RS52518B (sr) 2007-04-23 2013-04-30 Janssen Pharmaceutica N.V. Derivati 4-alkoksipiridazina kao brzo disocirajući dopamin 2 receptorski antagonisti
RU2489431C2 (ru) * 2007-04-23 2013-08-10 Янссен Фармацевтика Н.В. Тиа(диа)золы как быстро диссоциирующие антагонисты рецептора допамина 2
CN101663291A (zh) * 2007-04-23 2010-03-03 詹森药业有限公司 作为快速离解的多巴胺2受体拮抗剂的吡啶衍生物
CA2687931C (en) * 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
JP5417439B2 (ja) * 2008-07-03 2014-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ５−ｈｔ６受容体アンタゴニストとしての置換された６−（１−ピペラジニル）−ピリダジン類
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
LT2307374T (lt) * 2008-07-31 2017-04-25 Janssen Pharmaceutica Nv Piperazin-1-il-trifluormetil-pakeistieji piridinai kaip greitai disocijuojantys dopamino 2 receptoriaus antagonistai
PL2379525T3 (pl) 2008-12-19 2016-01-29 Centrexion Therapeutics Corp Cykliczne pirymidyno-4-karboksamidy jako antagoniści receptora CCR2 do leczenia stanów zapalnych, astmy oraz COPD
EA020847B1 (ru) 2009-10-30 2015-02-27 Янссен Фармацевтика Нв ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE10
AU2010332969B2 (en) 2009-12-17 2015-02-12 Centrexion Therapeutics Corporation New CCR2 receptor antagonists and uses thereof
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
ES2855575T3 (es) 2012-06-26 2021-09-23 Janssen Pharmaceutica Nv Combinaciones que comprenden compuestos de 4-metil-[1,2,4]triazolo[4,3-a]quinoxalina como inhibidores de PDE2 e inhibidores de PDE10 para su uso en el tratamiento de trastornos neurológicos o metabólicos
JP6174695B2 (ja) 2012-07-09 2017-08-02 ヤンセン ファーマシューティカ エヌ．ベー． ホスホジエステラーゼ１０酵素の阻害剤
CA2990460C (en) 2015-07-02 2023-10-17 Centrexion Therapeutics Corporation (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate
US20180350708A1 (en) * 2017-06-06 2018-12-06 Powertech Technology Inc. Package structure and manufacturing method thereof
EP4574152A1 (en) 2023-12-22 2025-06-25 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Potassium channel activators for use in the treatment of epileptic disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009025A2 (en) * 1997-08-15 1999-02-25 Pfizer Products Inc. 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4 receptor

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933823A (en) * 1971-03-29 1976-01-20 E. R. Squibb & Sons, Inc. Isoxazolopyridine ketone derivatives
DE2341965C3 (de) * 1973-08-20 1979-01-25 C.H. Boehringer Sohn, 6507 Ingelheim 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen
US4197304A (en) * 1975-09-23 1980-04-08 Janssen Pharmaceutica N.V. N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
NO147672C (no) 1975-09-23 1983-05-25 Janssen Pharmaceutica Nv Analogifremgangsmaate for fremstilling av n-aryl-n-(1-l1-4-piperidinyl)-arylacetamider
EG12406A (en) * 1976-08-12 1979-03-31 Janssen Pharmaceutica Nv Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides
DE3218482A1 (de) 1982-05-15 1983-11-17 Bayer Ag, 5090 Leverkusen Substituierte 5-trifluormethyl-1,3,4-thiadiazol-2-yloxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
ES8802151A1 (es) 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
PT93060B (pt) 1989-02-07 1995-12-29 Sanofi Sa Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem
US5461053A (en) * 1989-02-07 1995-10-24 Sanofi Pyridazine derivatives
GB9008850D0 (en) * 1990-04-19 1990-06-13 Janssen Pharmaceutica Nv Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones
GB9216298D0 (en) 1991-08-15 1992-09-16 Ici Plc Piperidine derivatives
AU684874B2 (en) 1993-12-28 1998-01-08 Pharmacia & Upjohn Company Heterocyclic compounds for the treatment of cns and cardiovascular disorders
DE4425145A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung von Thiazol- und Thiadiazolverbindungen
TW406075B (en) 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5753679A (en) 1995-05-10 1998-05-19 Hoffmann-La Roche Inc. Benzyl-piperidine derivatives
MY116093A (en) * 1996-02-26 2003-11-28 Upjohn Co Azolyl piperazinyl phenyl oxazolidinone antimicrobials
TW504510B (en) 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
KR100261139B1 (ko) 1998-01-16 2000-08-01 황준수 신규한 알릴티오피리다진 유도체 및 그의 제조방법
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US7053089B2 (en) 2001-02-23 2006-05-30 Merck & Co., Inc. N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
MXPA04003330A (es) 2001-10-09 2004-07-08 Kyorin Seiyaku Kk 4-(2-furoil) aminopiperidinas novedosas, compuestos intermedios en la sintesis de las mismas, proceso para producirlas y su uso medicinal.
GB0127832D0 (en) 2001-11-20 2002-01-09 Jagotec Ag Method for the preparation of pharmaceutical nanosuspensions
US7812035B2 (en) 2001-12-11 2010-10-12 Sepracor Inc. 4-substituted piperidines, and methods of use thereof
EP1467981A1 (en) 2002-01-25 2004-10-20 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
EP1474401A2 (en) 2002-02-05 2004-11-10 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
US20030236259A1 (en) 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
US6855709B2 (en) 2002-02-22 2005-02-15 Pharmacia & Upjohn Company Pyridyl sulfone derivatives
SE0201544D0 (sv) 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
ATE551053T1 (de) * 2002-09-26 2012-04-15 Mandom Corp Antiseptische bakterizide, und kosmetika, arzneimittel und lebensmittel, die die antiseptischen bakterizide enthalten
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
BRPI0408704A (pt) 2003-03-24 2006-03-07 Hoffmann La Roche benzil-piridazinonas como inibidores de transcriptase reversa
DE50312980D1 (de) 2003-05-07 2010-09-23 Kemira Pigments Oy Ftstoffen und aromen
CA2524498C (en) 2003-05-08 2012-01-24 Kyorin Pharmaceutical Co., Ltd. 4-(2-furoyl)aminopiperidine compound useful as therapeutic agent for itching
WO2005005779A2 (en) 2003-07-14 2005-01-20 Genesis Mining Technologies (Pty) Ltd Dual retention cutting arrangement
KR20060054392A (ko) 2003-07-29 2006-05-22 노보 노르디스크 에이/에스 피리다지닐-피페라진 및 히스타민 ｈ３ 수용체 리간드로서그들의 사용
EP2316827B1 (en) 2003-07-30 2016-01-27 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
EP1653969A4 (en) 2003-08-07 2006-12-20 Japan Tobacco Inc PYRROLO 1,2-B PYRIDAZINE DERIVATIVES
US7863044B2 (en) 2003-10-24 2011-01-04 Tao Cheng p18 in stem cell manipulations
KR20070001976A (ko) 2004-02-10 2007-01-04 얀센 파마슈티카 엔.브이. 알파４ 인테그린의 길항제로서의 피리다지논 우레아
WO2005090317A1 (en) 2004-03-23 2005-09-29 F.Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
US20070225333A1 (en) 2004-04-28 2007-09-27 Bryans Justin S 3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor
AU2005249494A1 (en) 2004-05-28 2005-12-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
EP1807085B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
DK1805158T3 (en) 2004-10-29 2018-08-06 Kalypsys Inc SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR
JP2008534640A (ja) * 2005-04-05 2008-08-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー タンパク質の機能部位またはエピトープの遮蔽方法
ATE450526T1 (de) 2005-06-20 2009-12-15 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
CA2658960A1 (en) 2006-08-15 2008-02-21 Alfred Binggeli Phenyl, pyridine and quinoline derivatives
US8058243B2 (en) * 2006-10-13 2011-11-15 Hsc Research And Development Limited Partnership Method for treating a brain cancer with ifenprodil
TW200829566A (en) 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
JO2642B1 (en) * 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) * 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
RU2489431C2 (ru) * 2007-04-23 2013-08-10 Янссен Фармацевтика Н.В. Тиа(диа)золы как быстро диссоциирующие антагонисты рецептора допамина 2
CN101663291A (zh) * 2007-04-23 2010-03-03 詹森药业有限公司 作为快速离解的多巴胺2受体拮抗剂的吡啶衍生物
RS52518B (sr) * 2007-04-23 2013-04-30 Janssen Pharmaceutica N.V. Derivati 4-alkoksipiridazina kao brzo disocirajući dopamin 2 receptorski antagonisti
JP2010539218A (ja) * 2007-09-20 2010-12-16 グラクソ グループ リミテッド Ｍ１受容体にて活性を有する化合物および医薬としてのそれらの使用
JP5417439B2 (ja) * 2008-07-03 2014-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ５−ｈｔ６受容体アンタゴニストとしての置換された６−（１−ピペラジニル）−ピリダジン類
LT2307374T (lt) 2008-07-31 2017-04-25 Janssen Pharmaceutica Nv Piperazin-1-il-trifluormetil-pakeistieji piridinai kaip greitai disocijuojantys dopamino 2 receptoriaus antagonistai

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009025A2 (en) * 1997-08-15 1999-02-25 Pfizer Products Inc. 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives interacting with the dopamine d4 receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MORAGUES J ET AL.: "DOPAMINERGIC ACTIVITY IN A SERIES OF N-SUBSTITUTED 2-AMINOPYRIMIDINES" FARMACO, EDIZIONE SCIENTIFICA, SOCIETA CHIMICA ITALIANA, PAVIA, IT, vol. 35, no. 11, 1980, pages 951-964, XP009032424 ISSN: 0430-0920 cited in the application page 959 - page 960; table II; compounds IA-IS *

Also Published As

Publication number Publication date
GT200800033A (es) 2009-08-20
HRP20110226T1 (hr) 2011-05-31
UA94058C2 (ru) 2011-04-11
EP1943242B1 (en) 2011-01-12
ECSP088396A (es) 2008-05-30
HK1124317A1 (en) 2009-07-10
US20150141432A1 (en) 2015-05-21
AU2006307930A1 (en) 2007-05-03
US8940743B2 (en) 2015-01-27
US9468640B2 (en) 2016-10-18
DK1943242T3 (da) 2011-04-26
DE602006019624D1 (de) 2011-02-24
EP1943242A1 (en) 2008-07-16
CN101291925B (zh) 2013-04-10
NZ566785A (en) 2010-03-26
BRPI0617787A2 (pt) 2009-12-01
US20170022181A1 (en) 2017-01-26
PT1943242E (pt) 2011-04-06
SI1943242T1 (sl) 2011-05-31
KR101351910B1 (ko) 2014-01-16
CA2623160C (en) 2013-10-15
CR10020A (es) 2009-01-16
PL1943242T3 (pl) 2011-06-30
KR20080067658A (ko) 2008-07-21
CY1111977T1 (el) 2015-11-04
NO20082350L (no) 2008-07-01
EA015681B1 (ru) 2011-10-31
ZA200803668B (en) 2009-09-30
RS51674B (sr) 2011-10-31
AR058151A1 (es) 2008-01-23
AU2006307930B2 (en) 2011-10-06
MY145609A (en) 2012-03-15
JO2769B1 (en) 2014-03-15
CN101291925A (zh) 2008-10-22
US9751860B2 (en) 2017-09-05
WO2007048779A1 (en) 2007-05-03
ATE495167T1 (de) 2011-01-15
CA2623160A1 (en) 2007-05-03
JP5140598B2 (ja) 2013-02-06
HN2008000646A (es) 2011-02-16
US20080227791A1 (en) 2008-09-18
EA200801184A1 (ru) 2008-08-29
ES2359020T3 (es) 2011-05-17
TWI399373B (zh) 2013-06-21
IL191016A (en) 2013-10-31
TW200732321A (en) 2007-09-01
JP2009514815A (ja) 2009-04-09
AP2008004441A0 (en) 2008-04-30

Similar Documents

Publication Publication Date Title
ZA200803668B (en) Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists
ZA200800320B (en) Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
ZA200709147B (en) Pyrimidindione derivatives as prokineticin 2 receptor antagonists
IL200310A (en) 4-aryl-6-piperazine-1-yl-pyridines as fast-breaking dopamine 2 antagonists
IL201663A0 (en) 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
ZA200801432B (en) Carboxamide derivatives as muscarinic receptor antagonists
IL187426A0 (en) Piperidin-4-yl-amide derivatives and their use as sst receptor subtype 5 antagonists
ZA200705085B (en) 2,3,4,9-Tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists
IL188806A0 (en) Substituted piperazines as metabotropic glutamate receptor antagonists
IL192308A0 (en) Oxazoloisoquinoline derivatives as thrombin receptor antagonists
SI2307374T1 (sl) Piperazin-1-il-trifluorometil-substituirani-piridini kot hitro disociirajoči antagonisti receptorja dopamin 2
PL2091938T3 (pl) Piperydynyloaminipirazyny i ich zastosowanie jako szybko dysocjujących antagonistów receptora dopaminy 2
AP2006003840A0 (en) Indole-2-carboxamidine derivatives as NMDA receptor antagonists
IL201661A0 (en) Thia(dia) zoles as fast dissociating dopamine 2 receptor antagonists
IL201662A0 (en) Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
ZA200802339B (en) Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists
IL198544A0 (en) Spiro-piperidine derivatives as via receptor antagonists
PT1912976E (pt) Derivados de indol-3-il-carboni-piperidin-benzimidazole como antagonistas dos receptores v1a
ZA200800516B (en) Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives as V1a receptor antagonists